Last reviewed · How we verify

Chronic Pain with Opioid Tolerance — Treatment Landscape & Competitive Intelligence

Chronic Pain with Opioid Tolerance (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic Pain with Opioid Tolerance, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Dilaudid-Hp Hydromorphone Hydrochloride Fresenius Kabi Opioid agonist Mu-opioid receptor 1984-01-01
Dilaudid-Hp HYDROMORPHONE Fresenius Kabi Opioid Agonist mu-opioid receptor 1984-01-01
Subutex BUPRENORPHINE Purdue Pharma Lp Partial Opioid Agonist mu-opioid receptor, kappa-opioid receptor 1981-01-01
Subutex Buprenorphine Hydrochloride Indivior partial opioid agonist mu-opioid receptor, kappa-opioid receptor 1981-01-01
Duragesic fentanyl Johnson & Johnson (Janssen Pharmaceutica) Synthetic opioid analgesic D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor 1968-01-01
Opana Er OXYMORPHONE Endo Opioid Agonist Mu-type opioid receptor 1959-01-01
MS Contin morphine sulfate Generic (multiple manufacturers) Opioid analgesic Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor 1941-01-01
Naltrexon Naltrexon Institute of Liver and Biliary Sciences, India Neuronal acetylcholine receptor subunit alpha-7, Cytochrome P450 2D6, Delta-type opioid receptor
OXYCONTIN® OXYCONTIN® Mundipharma (China) Pharmaceutical Co. Ltd Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
OxyContin oxycodone Purdue Pharma Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Fresenius Kabi · 2 drugs in Chronic Pain with Opioid Tolerance
  2. Generic (multiple manufacturers) · 1 drug in Chronic Pain with Opioid Tolerance
  3. Indivior · 1 drug in Chronic Pain with Opioid Tolerance
  4. Institute of Liver and Biliary Sciences, India · 1 drug in Chronic Pain with Opioid Tolerance
  5. Johnson & Johnson (Janssen Pharmaceutica) · 1 drug in Chronic Pain with Opioid Tolerance
  6. Mundipharma (China) Pharmaceutical Co. Ltd · 1 drug in Chronic Pain with Opioid Tolerance
  7. Oslo University Hospital · 1 drug in Chronic Pain with Opioid Tolerance
  8. Pfizer · 1 drug in Chronic Pain with Opioid Tolerance
  9. Purdue Pharma · 1 drug in Chronic Pain with Opioid Tolerance
  10. Endo · 1 drug in Chronic Pain with Opioid Tolerance
  11. Purdue Pharma Lp · 1 drug in Chronic Pain with Opioid Tolerance

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic Pain with Opioid Tolerance:

Cite this brief

Drug Landscape (2026). Chronic Pain with Opioid Tolerance — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-pain-with-opioid-tolerance. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing